Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOIO reduced-intensity versus standard checkpoint immunotherapy maintenance trial
2024-513707-14-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab, dostarlimab, atezolizumab, cemiplimab, nivolumab and 2 more in bronchial carcinoma, renal cell carcinoma (RCC), head and neck cancer (HNC) and 15 more (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
bronchial carcinomarenal cell carcinoma (RCC)head and neck cancer (HNC)transitional cell carcinoma (TCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-513707-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513707-14-00.